U.S. Markets open in 5 hrs 32 mins

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
21.66-0.55 (-2.48%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close22.21
Open22.20
Bid0.00 x 900
Ask0.00 x 1300
Day's Range21.50 - 22.38
52 Week Range10.94 - 31.18
Volume331,858
Avg. Volume594,588
Market Cap2.526B
Beta (5Y Monthly)0.76
PE Ratio (TTM)25.48
EPS (TTM)0.85
Earnings DateMay 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
  • Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?

    Corcept Therapeutics (CORT) has been struggling lately, but the selling pressure may be coming to an end soon

  • Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
    GlobeNewswire

    Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

    MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 6, 2021. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time. Click to Join Meeting Alternatively, you may dial 1-888-204-4368 from the United States or 1-313-209-4906 internationally approximately 15 minutes before the start of the call. The passcode will be 8720277. A replay will be available through May 20, 2021 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 8720277. About Corcept Therapeutics Incorporated Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders. CONTACT: Corcept Therapeutics Investor Relations ir@corcept.com www.corcept.com

  • Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline
    Zacks

    Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline

    Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.